Drugmaker Moderna announced Monday that its COVID-19 vaccine is safe and generates a strong immune response in children ages 6-11.

Moderna tested a 50 microgram dose of the vaccine, which the FDA authorized last week as a booster, in a study of more than 4,700 children. The two doses were given 28 days apart.

The vaccine was "generally well tolerated," according to Moderna, with results similar to those experienced in adolescents and adults. The majority of side effects were "mild or moderate in severity," the most common of which being fever, fatigue, headache and injection site pain.

The company plans to submit its data, which has not yet been peer reviewed, to regulators worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

“We are encouraged by the immunogenicity and safety profile of mRNA-1273 in children aged 6 to under 12 years and are pleased that the study met its primary immunogenicity endpoints,” Stéphane Bancel, Chief Executive Officer of Moderna said in a statement. “We look forward to filing with regulators globally and remain committed to doing our part to help end the COVID-19 pandemic with a vaccine for adults and children of all ages.”

The results come one day before a panel of advisers to the FDA is scheduled to discuss authorizing the Pfizer-BioNTech COVID-19 vaccine for kids 5-11.

This is a developing story. Check back later for further udpates.